» Articles » PMID: 23703144

Long-term Outcome of Patients with Aortic Aneurysms Taking Low-dose Aspirin: a Population-based Cohort Study

Overview
Journal J Investig Med
Publisher Sage Publications
Specialty General Medicine
Date 2013 May 25
PMID 23703144
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Limited studies evaluated the association between low-dose aspirin use and abdominal aortic aneurysm (AAA), thoracoabdominal aortic aneurysm (TAAA), and thoracic aortic aneurysm (TAA) treatment. We conducted this study to investigative the association of low-dose aspirin in terms of preventing death and exacerbation of different aortic aneurysms.

Methods: This retrospective study identified aortic aneurysm cases between 1999 and 2006 from the National Health Insurance Research Database and used time-dependent methods to determine whether the use of low-dose aspirin reduced the risk of outcomes. Primary outcomes, including a composite outcome of death, aortic dissection, a rupture event, an unruptured event, or surgical repair, and secondary outcomes, the composite end point of death and readmission for aortic aneurysm events, were estimated separately.

Results: Two hundred eighty-seven cases were identified. The hazard ratio for the primary outcome in patients taking low-dose aspirin in AAA/TAAA patients at each 90-day interval based on the time-dependent analysis was 1.000 (95% confidence interval [CI], 0.994-1.005), and in TAA patients 1.010 (95% CI, 0.994-1.026) compared with those with no exposure. In terms of the secondary outcomes, the hazard ratio for all-cause mortality was 0.995 (95% CI, 0.988-1.003) for AAA/TAAA patients and 1.008 (95% CI, 0.991-1.026) for TAA patients.

Conclusions: From a national population database, we did not find an association between low-dose aspirin exposure and mortality or exacerbation in different aortic aneurysms by using time-dependent analysis. However, adjustments for aneurysms size and smoking status could not be made, which may limit the validity of the study.

Citing Articles

Alkaline ceramidase 1-mediated platelet ceramide catabolism mitigates vascular inflammation and abdominal aortic aneurysm formation.

Zhang X, Gong Z, Shen Y, Cai Z, Yang L, Zhang T Nat Cardiovasc Res. 2024; 2(12):1173-1189.

PMID: 39196139 DOI: 10.1038/s44161-023-00364-1.


Effect of Antiplatelet Agents on Abdominal Aortic Aneurysm Process: A Systematic Review and Meta-Analysis.

Yang Y, Li C, Wu Z, Chen Z, Diao Y, Li Y Rev Cardiovasc Med. 2024; 24(12):357.

PMID: 39077092 PMC: 11272864. DOI: 10.31083/j.rcm2412357.


Antiplatelet Therapy, Abdominal Aortic Aneurysm Progression, and Clinical Outcomes.

Hariri E, Matta M, Layoun H, Badwan O, Braghieri L, Owens 3rd A JAMA Netw Open. 2023; 6(12):e2347296.

PMID: 38085542 PMC: 10716735. DOI: 10.1001/jamanetworkopen.2023.47296.


The Detrimental Role of Intraluminal Thrombus Outweighs Protective Advantage in Abdominal Aortic Aneurysm Pathogenesis: The Implications for the Anti-Platelet Therapy.

Ma X, Xia S, Liu G, Song C Biomolecules. 2022; 12(7).

PMID: 35883500 PMC: 9313225. DOI: 10.3390/biom12070942.


Acetylsalicylic Acid Is Associated With a Lower Prevalence of Ascending Aortic Aneurysm and a Decreased Aortic Expression of Cyclooxygenase 2.

Granath C, Freiholtz D, Bredin F, Olsson C, Franco-Cereceda A, Bjorck H J Am Heart Assoc. 2022; 11(9):e024346.

PMID: 35470674 PMC: 9238591. DOI: 10.1161/JAHA.121.024346.